Using remote monitoring to manage chronic immunosuppressive therapy
Integration of Remote Monitoring in the Management of Chronic Immunosuppressive Therapy in Patients With Rheumatologic Diseases: Comparison With Standard Management
This study tests whether using remote monitoring can help people with chronic autoimmune diseases better manage their new immunosuppressive medications and improve their treatment results.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 190 (estimated) |
| Sex | All |
| Sponsor | University Of Perugia Academic / other |
| Drugs / interventions | adalimumab, golimumab, certolizumab, tocilizumab, secukinumab, ixekizumab, ustekinumab, guselkumab, risankizumab, Belimumab, Anifrolumab, tofacitinib, baricitinib, upadacitinib, filgotinib, Methotrexate |
| Locations | 1 site (Perugia, PG) |
| Trial ID | NCT06544343 on ClinicalTrials.gov |
What this trial studies
This study focuses on patients with chronic autoimmune diseases who are starting new immunosuppressive medications. It aims to integrate remote monitoring techniques to track patient responses and side effects, potentially improving treatment outcomes. By utilizing both remote and on-site monitoring, the study seeks to enhance the management of these long-term therapies, which often require adjustments based on individual patient responses. The goal is to optimize treatment efficacy while minimizing adverse effects.
Who should consider this trial
Good fit: Ideal candidates include patients diagnosed with rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus, systemic sclerosis, or spondyloarthritis who are beginning a new immunosuppressive therapy.
Not a fit: Patients who are not starting a new immunosuppressive medication or those unable to use remote monitoring devices may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more personalized and effective management of chronic autoimmune diseases, improving patients' quality of life.
How similar studies have performed: While the integration of remote monitoring in chronic disease management is a growing field, this specific approach to immunosuppressive therapy management is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Any patient with one of the following conditions * Rheumatoid Arthritis * Psoriatic Arthritis * Spondyloarthritis * Ankylosing Spondylitis * Systemic Sclerosis * Systemic Lupus Erythematosus * Sjogren's Disease who are prescribed a new immunosuppressive medication for the treatment of their disease among the following: * Methotrexate * Sulfasalazine * Leflunomide * Mycophenolate Mofetil * Azathioprine * Cyclosporine A * Tacrolimus * TNF inhibitors (etanercept, adalimumab, golimumab, certolizumab pegol) * IL6 inhibitors (tocilizumab) * IL-17 inhibitors (secukinumab, ixekizumab) * IL-23 inhibitors (ustekinumab, guselkumab, risankizumab) * JAK-inhibitors (tofacitinib, baricitinib, upadacitinib, filgotinib) * Belimumab * Anifrolumab Exclusion Criteria: * Treatment with a medication not approved for the condition * Inability to use a device for remote call, not even with the help of a caregiver
Where this trial is running
Perugia, PG
- Rheumatology Unit - Perugia Univeristy Hospital — Perugia, Pg, Italy (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.